Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Rocuronium”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 307 records · Page 17Linked to original sources
PubMed2002

Rocuronium-induced generalized spontaneous movements cause pulmonary aspiration.

Rapid-sequence induction with cricoid pressure is a standard procedure for inducing anesthesia in patients with a potentially full stomach. During the induction period, if the patient develops generalized movements of the body, the pressure level of the cricoid may change unexpectedly. As a result, the increase in intragastric pressure may cause gastric regurgitation and consequent pulmonary aspiration. Rocuronium has been widely used as an alternative to succinylcholine during the induction of anesthesia. However, most patients who received rocuronium complained of severe burning pain in their arm during intravenous injection. Even after the administration of the induction agents, rocuronium injection can also cause withdrawal of the hand or other generalized movements of the body. We describe a case of gastric regurgitation with pulmonary aspiration following generalized spontaneous movements associated with rocuronium injection in a girl who received pediatric emergent surgery.

Androstanols↗
PubMedDate not supplied

[Rocuronium (esmerone) in anesthesia during surgery under extracorporeal circulation].

The study was undertaken to examine the myoplegic, hemodynamic, and histamine-releasing effects of the new aminosteroidal myorelaxant Rocuronium (esmerone, Organon firm) used to maintain anesthesia in cardiac surgical patients by orienting to early tracheal extubation. Twenty two patients aged 50 +/- 3 years operated on under extracorporeal circulation were examined. At the initial stage of maintenance, the agent in a dose of 0.6 mg/kg failed to affect cardiac pump function and to elevate plasma histamine levels. A moderate vagolytic effect was shown in 45% of cases. The incidence of myoplegia reduced in patients with significant circulatory insufficiency. In the preperfusion period, Rocuronium in a dose of 10.2 +/- 0.9 micrograms/kg/min blocked neuromuscular conduction (NMC) at a level of 5.1 +/- 1.8 to 19.2 +/- 3.5%. During hypothermic extracorporeal circulation and postperfusion period, the dosage of the myorelaxant substantially decreased. After termination of Rocuronium infusion, the time of up to 95%-recovery of NMC was 63 +/- 6 min. Early tracheal extubation was conducted in 68% of the patients 69 +/- 7.6 min after the end of the operation. Residual myoplegia was absent. The predictable recovery of NMC following the use of Rocuronium creates conditions for early activation of patients operated on under extracorporeal circulation.

Androstanols↗
PubMed2003

Priming rapacuronium: a comparison with rocuronium and mivacurium.

The aim of this study is to present the pharmacodynamics of the priming principle using rapacuronium and a comparison with rocuronium and mivacurium. After induction, 120 patients were randomly allocated to six similar groups. Groups 1 and 2 received rapacuronium 1000 micrograms.Kg-1 as a bolus or primed with 100 micrograms.Kg-1. To groups 3 and 4, rocuronium 400 micrograms.Kg-1 were given as a bolus or primed with 60 micrograms.Kg-1, finally mivacurium 100 micrograms.Kg-1 was used for groups 5 and 6 by bolus or primed with 10 micrograms.Kg-1. Neuromuscular function was monitored by electromyography and it was demonstrated that time to 80% blockade, is significantly shorter after priming: 137 (bolus) vs 101 seconds (priming) for rapacuronium, 160 vs 90 for rocuronium and 196 vs 118 for mivacurium. Onset time was also statistically accelerated by priming: 229 seconds vs 183, 289 vs 203 and 298 vs 252 respectively. No significant change was noticed in maximal blockade and clinical duration due to priming. During early onset, only the mivacurium patients showed a statistical difference in train of four fade between bolus and priming. In conclusion, priming hasten early and maximal effect produced by rapacuronium, rocuronium and mivacurium without any change in maximal blockade and clinical duration. Pre-synaptic effect does not explain consistently the mode of action of priming.

Adult↗
PubMed2004

Recovery from neuromuscular block after an intubation dose of cisatracurium and rocuronium in lumbar disc surgery.

BACKGROUND AND OBJECTIVE: Residual muscle paralysis remains a concern for anaesthesiologists. This study investigated the recovery from neuromuscular block (NMB) after an intubation dose of cisatracurium (C) or rocuronium (R) in 32 patients undergoing lumbar disc surgery. METHODS: Anaesthesia was induced with propofol and sufentanil, and maintained with sevoflurane in nitrous oxide/oxygen. Patients were randomised to receive twice the ED95 of either cisatracurium (GC) or rocuronium (GR) before tracheal intubation. After placement in prone position, neuromuscular transmission was monitored at the wrist by accelerometry. NMB was antagonised when the TOF ratio (TOFR) was < 0.75 at muscle closure. The time from muscle relaxant to muscle closure, and to TOFR of 0.25 and of 0.50 were recorded. Data were analysed using Student's t-tests, chi-squared tests and two-way mixed-designed ANOVA's. The prediction probability (Pk) of the times from muscle relaxant to muscle closure, and to TOFR of 0.25 for the necessity to antagonize NMB was calculated in both groups. P < 0.05 was considered statistically significant. RESULTS: NMB was antagonized in 8 (GC) and 6 (GR) patients, respectively. The time from muscle relaxant to muscle closure was shorter in patients whose NMB was antagonized. The Pk of this time was significant in GC (0.85) but not in GR (0.69). In GR contrarily to GC, the times to a TOFR of 0.25 and 0.50 were longer in patients whose NMB was antagonized. The Pk of the time to TOFR of 0.25 was significant in GR (0.95) but not in GC (0.64). CONCLUSIONS: A single dose of cisatracurium or rocuronium may be associated to some degree of NMB at the end of lumbar surgery, depending on the duration of surgery and on the duration of action of the muscle relaxant which is more variable for rocuronium than for cisatracurium.

Adult↗
PubMedDate not supplied

[Speed of intubation using a new neuromuscular blocker. Rocuronium bromide (ORG 9426)].

OBJECTIVES: To compare intubation conditions and neuromuscular parameters, patency time, maximum level of block, time and clinical duration of effect for rocuronium bromide 0.6 mg/kg (ORG 9426) versus equally potent doses of vecuronium and atracurium under similar experimental conditions. PATIENTS AND METHODS: Sixty patients were divided into three groups of twenty. Intubation conditions were scored on a scale of 3-12 points based on relaxation of the vocal cords, presence of cough and ease of laryngoscopy after 60 or 90 sec. Neuromuscular parameters were obtained by integrated electromyography of the thenar and hypothenar muscle structure, evoked by supramaximal stimuli of the cubital nerve in train of four (2 Hz in 2 sec). The shape of the electrocardiographic curve, heart rate and mean arterial pressure measured non-invasively were recorded throughout the surgical procedure. RESULTS: Means of onset times and times of effect for rocuronium (33 and 135 sec) were significantly lower than those obtained with vecuronium and atracurium. Clinical duration, free of hemodynamic changes, was similar in the three groups. Rocuronium produces excellent intubation conditions 60 sec after administration, although at this point peripheral muscle block was only partial. Rocuronium may be superior to other neuromuscular blockers available today as a result of the speed with which it affords excellent intubation conditions.

Adult↗
PubMed1994

Dose-response relationship and time course of action of rocuronium bromide in perspective.

The available evidence indicates that rocuronium is one of the least potent non-depolarizing muscle relaxants, having a clinical duration, recovery index and reversal time similar to those of atracurium and vecuronium. The onset time, however, is significantly shorter than that of currently used non-depolarizing muscle relaxants. Rocuronium seems to be potentiated by the inhalational anaesthetics to the same degree as vecuronium. This effect is clinically most significant when using a continuous infusion of rocuronium. There is no difference in potency of rocuronium between adult and elderly patients, but it is not clear yet whether the potency differs between adults and neonates, infants or children. The onset time, duration of action, and recovery index are prolonged in elderly patients and the onset time, duration of action, and recovery index are longer in infants than in children.

Adolescent↗
PubMed1994

The pharmacology of rocuronium bromide (ORG 9426).

Rocuronium is a new nondepolarizing neuromuscular blocking drug. Its onset of action is comparable to that of succinylcholine, with good-to-excellent intubating conditions possible 1 minute after doses two times the ED95 (600 micrograms/kg). The ED95 of rocuronium is essentially the same for children as for adults. Its duration of action is similar to vecuronium, and it is shorter for children than for adults. Rocuronium is readily reversed with conventional doses of cholinesterase-inhibiting drugs. A new agent, rocuronium possesses a very stable cardiovascular profile and a rapid onset of action. It may be useful for rapid sequence intubation without unacceptable delays in the spontaneous recovery of neuromuscular function.

Adult↗
PubMed1993

[Rocuronium, the "ideal" nondepolarizing muscle relaxant?].

Rocuronium bromide (Org 9426) is a new, non-depolarising steroidal muscle relaxant that is currently undergoing extensive clinical trials worldwide. Since it is expected to be introduced into clinical practice in the near future, the purpose of this review is to give a summary of the currently available information on this promising new compound. The search for the so-called ideal muscle relaxant [34] in the last years was focused on a non-depolarising compound that could replace succinylcholine for rapid intubation. The currently most frequently used agents vecuronium and atracurium have an onset of action that usually does not allow intubation earlier than 3 min after its injection. Recent animal [40] and human [10] studies have shown that development of neuromuscular blockade of the vocal cords and laryngeal muscles can be faster than that of the peripheral skeletal muscles. This would mean that intubation can be performed before complete relaxation of the adductor muscle of the thumb is achieved. Rocuronium is the 2-morpholino, 16 N-allyl-pyrrolidino derivative of the 3-hydroxy metabolite of vecuronium. In initial clinical studies [13, 42] its most impressive features appeared to be rapid onset time and, more importantly, the rapid development of good intubating conditions. Thirty to 90 s after the injection of 0.6 mg/kg (2 x ED90), rocuronium provided intubating conditions that were equal to those observed after succinylcholine [9, 17, 31, 38]. Although the onset time of rocuronium at the adductor pollicis muscle is slower than that of succinylcholine, intubation with this compound can be performed faster than with any other non-depolarising agent.(ABSTRACT TRUNCATED AT 250 WORDS)

Androstanols↗
PubMed1995

Dose-response, time-course of action and recovery of rocuronium bromide in children during halothane anaesthesia.

Two groups of children, aged 1-4 years (n = 28) and 5-10 years (n = 28), respectively, received at random one of four doses of rocuronium (0.12, 0.17, 0.22 or 0.27 mg kg-1). When maximum block was obtained, further rocuronium to a total dose of 0.5 mg kg-1 was given. At a spontaneous T1 recovery of 25% the block was reversed with atropine and neostigmine in half the patients. The remainder were allowed to recover spontaneously. There was no difference in potency in the two age groups. An ED50 of 0.2 mg kg-1 was estimated. The estimates of ED50 were model-dependent of approximately 0.32 mg kg-1. The maximum block was found significantly higher in the younger age group (99.0 +/- 1.5% (mean +/- SD)) as compared to the older group (97.5 +/- 2.3%), and the clinical duration was also longer (16.6 +/- 5.3 min vs. 13.3 +/- 3.8 min), respectively. There was no significant difference between the two age groups in duration90 (26.9 +/- 6.5 min, 22.5 +/- 6.7 min, respectively) and duration0.7 (27.6 +/- 6.0 min, 24.9 +/- 7.9 min, respectively). Recovery time25-75, recovery time25-90, but not recovery time25-0.7 were found significantly longer in the 1-4 year group as compared to the times in older children. Neostigmine administration reduced recovery time by approximately half to two-thirds. MAP was not influenced by rocuronium. Following the injection of rocuronium in the younger age group there was a 15% increase in heart rate compared to a 10% increase in the age group 5-10 years.

Androstanols↗
PubMed1995

Hypothermic cardiopulmonary bypass influences the concentration-response relationship and the biodisposition of rocuronium.

In 10 patients scheduled for elective coronary artery bypass grafting under midazolam-sufentanil anaesthesia, the influence of hypothermia on the plasma concentration-response and biodisposition of rocuronium were investigated. Neuromuscular function was monitored mechanomyographically. Plasma and urine concentrations of rocuronium were determined by high performance liquid chromatography. Hypothermic cardiopulmonary bypass prolonged the duration of action of maintenance doses and altered the plasma concentration-response relationship. The elimination and distribution half-lives, following the last maintenance dose after rewarming, and the urinary excretion of rocuronium were similar to values obtained during normothermia. A diminished hepatic uptake and storage in the liver of rocuronium during hypothermia may explain the more pronounced prolongation of the duration compared to that of other steroidal neuromuscular blocking agents.

Adjuvants, Anesthesia↗
PubMed1996

Comparison of neuromuscular block of atracurium and rocuronium in adults.

We studied the time-course of action of atracurium 0.5 mg kg-1 and rocuronium 0.6 mg kg-1 in 24 healthy adult patients. Anesthesia was induced with thiopentone and sufentanil, and maintained with 50% nitrous oxide and 1% enflurane in oxygen. Neuromuscular transmission was monitored by stimulating the ulnar nerve at the wrist and measuring the acceleration of the thumb using the TOF-Guard accelerograph monitor. Supramaximal stimuli of 0.2 ms duration were applied in a single twitch stimulation mode at 1 Hz frequency until completion of block, and in train-of four (TOF) sequence at 2 Hz every 15 sec thereafter. Onset time was longer with atracurium (mean +/- SD:90 +/- 18 sec) than with rocuronium (49 +/- 6 sec). Clinical duration of action (Tl25) was longer with atracurium (52.3 +/- 7.2 min) than with rocuronium (40.0 +/- 6.4 min). Recovery index (Tl25-Tl75) and time for TOF ratio to recover to 0.75 were 17.8 +/- 4.2 and 73.9 +/- 8.8 min with atracurium, and 13.8 +/- 4.1 and 70.4 +/- 14.1 min with rocuronium. The differences between both groups were statistically significant except the difference in the time for TOF to return to 0.75.

Adult↗
PubMed1997

[Rocuronium].

Rocuronium is a new nondepolarizing neuromuscular blocking agent (NDNMBA) that has recently been introduced for clinical use. Its main advantage over other such agents is its rapid onset of action, which may lead to its use as the relaxant of choice when rapid intubation is required. An additional advantage is that, unlike other amino-steroidal NDNMBAs, rocuronium does not produce active metabolites. The potency of rocuronium is five times lower than that of vecuronium and its half life at its place of effect is shorter. Selectivity for the laryngeal muscle system is greater, possibly explaining the rapid onset observed. Hemodynamic stability, along with the absence of histamine release even at doses as high as 4 to 5 ED95, allow it to be used in high risk patients. Successful use has been reported in emergency surgery in patients with full stomachs, in cesarean deliveries, in cardiovascular surgery, and in liver, kidney and other transplants. Rocuronium administered in repeated doses or in continuous infusion provides adequate muscle relaxation over the required period, with predictable reversibility of effects.

Age Factors↗
PubMed1997

Residual neuromuscular blockade after cardiac surgery: pancuronium vs rocuronium.

PURPOSE: To determine the incidence of residual neuromuscular blockade after cardiac surgery in patients receiving either rocuronium or pancuronium for muscle relaxation. METHODS: In a prospective, controlled, double-blind study, 20 patients undergoing coronary artery bypass were randomized to receive either rocuronium (n = 10) or pancuronium (n = 10) during surgery. Anaesthesia was induced with sufentanil, benzodiazepine and propofol or ketamine, and maintained with air/O2/sufentanil/isoflurane. Neuromuscular blockade was induced with 0.1 ml.kg-1 from blinded syringes containing recuronium (6 mg.ml-1) (Group R) or pancuronium (1 mg.ml-1) (Group P). Relaxants were administered according to clinical criteria and reversal agents were not given. After surgery, neuromuscular transmission was assessed by train-of-four stimulation of the ulnar nerve/adductor pollicis EMG (Datex Relaxograph). Mean values from three trains of stimuli were recorded and repeated 30 min later if TOF ratio was < 0.7. Time to extubation was recorded. RESULTS: On arrival in the ICU, nine of 10 patients in group R but only three of 10 patients in group P demonstrated four visible responses (P < 0.05). Mean TOF ratio in group P, 0.03 +/- 0.05, was less than in group R, 0.68 +/- 0.34 (P < 0.001). All patients in group P and 4 of 10 patients in group R had TOF ratio < 0.7 (P = 0.01). Time to extubation in group P (median 18, range 6-48 hr) was not statistically different from that in group R (14, 5-44 hr). CONCLUSION: Residual neuromuscular block, TOF ratio < 0.7, is common after cardiac surgery but the incidence is less when pancuronium is replaced by rocuronium.

Aged↗
PubMed2001

Neostigmine antagonism of rocuronium block during anesthesia with sevoflurane, isoflurane or propofol.

PURPOSE: To examine the influence of continuing administration of sevoflurane or isoflurane during reversal of rocuronium induced neuromuscular block with neostigmine. METHODS: One hundred and twenty patients, divided into three equal groups, were randomly allocated to maintenance of anesthesia with sevoflurane, isoflurane or propofol. Neuromuscular block was induced with rocuronium and monitored using train-of-four (TOF) stimulation of the ulnar nerve and recording the force of contraction of the adductor pollicis muscle. Neostigmine was administered when the first response in TOF had recovered to 25%. At this time the volatile agent administration was stopped or propofol dosage reduced in half the patients in each group (n = 20 in each group). The times to attain TOF ratio of 0.8, and the number of patients attaining this end point within 15 min were recorded. RESULTS: The times (mean +/- SD) to recovery of the TOF ratio to 0.8 were 12.0 +/- 5.5 and 6.8 +/- 2.3 min in the sevoflurane continued and sevoflurane stopped groups, 9.0 +/- 8.3 and 5.5 +/- 3.0 min in the isoflurane continued and isoflurane stopped groups, and 5.2 +/- 2.8 and 4.7 +/- 1.5 min in the propofol continued and propofol stopped groups (P < 0.5-01). Only 9 and 15 patients in the sevoflurane and isoflurane continued groups respectively had attained a TOF ratio of 0.8 within 15 min (P < 0.001 for sevoflurane). CONCLUSIONS: The continued administration of sevoflurane, and to a smaller extent isoflurane, results in delay in attaining adequate antagonism of rocuronium induced neuromuscular block.

Adolescent↗
PubMedDate not supplied

Induction with sevoflurane-remifentanil is comparable to propofol-fentanyl-rocuronium in PONV after laparoscopic surgery.

PURPOSE: To compare sevoflurane-remifentanil induction and propofol-fentanyl-rocuronium induction with regards to the frequency of moderate to severe postoperative nausea and vomiting (PONV) in the first 24 hr after laparoscopic day surgery. METHODS: After informed consent, 156 ASA physical status class I to III patients undergoing laparoscopic cholecystectomy or tubal ligation were randomized to either induction with sevoflurane 8%, N(2)O 67% and iv remifentanil 1 to 1.5 microg.kg(-1) or induction with iv fentanyl 2 to 3 microg.kg(-1), propofol 2 mg.kg(-1), and rocuronium 0.3 to 0.5 mg.kg(-1). All patients received iv ketorolac 0.5 mg.kg(-1) at induction and sevoflurane-N(2)O maintenance anesthesia with rocuronium as needed. PONV was treated with iv ondansetron, droperidol, or dimenhydrinate; postoperative pain was treated with opioid analgesics. Patients were followed for 24 hr with regards to PONV and pain. Intubating conditions, induction and emergence times, time to achieve fast-track discharge criteria, and drug costs were measured. RESULTS: No differences were seen between the two groups in their frequencies of 24-hr moderate to severe PONV and postoperative pain, or in their intubating conditions, induction and emergence times, and time to achieve fast-track discharge criteria. Patients undergoing sevoflurane-remifentanil induction received more morphine (11 mg vs 8 mg; P < 0.001) in the postanesthetic care unit. Sevoflurane-remifentanil induction resulted in similar anesthetic and total drug costs for both procedures. CONCLUSION: We did not demonstrate any difference in PONV, pain, or anesthetic/recovery times or costs between the sevoflurane and propofol groups. Sevoflurane-remifentanil induction is a feasible technique for anesthetic induction.

Adult↗
PubMed2000

Rocuronium anaphylaxis and multiple neuromuscular blocking drug sensitivities.

PURPOSE: To report a case of anaphylaxis to rocuronium and the sensitivities to multiple neuromuscular blocking drugs in a patient with no previous exposure to this group of drugs. We describe the current recommendations for both intraoperative and postoperative testing of these patients. CLINICAL FEATURES: A 36-yr-old man was admitted for repair of a ruptured Achilles tendon. Following induction of general anesthesia with fentanyl and propofol, 60 mg of rocuronium were given to facilitate tracheal intubation. He immediately became profoundly hypotensive with impalpable pulses, and blood pressure could not be recorded. Airway pressure increased markedly, and hand ventilation of the lungs became very difficult. His airway was secured and he was successfully resuscitated with 3 mg epinephrine and three litres crystalloid and colloid intravenous fluid therapy. His recovery in the intensive care unit was uneventful and the operation was performed four days later under spinal anesthesia. Subsequent skin prick testing, performed six weeks later, demonstrated strong positive weal and flare reactions to rocuronium, vecuronium and pancuronium, and some cross-reactivity with the benzylisoquinolinium group of muscle relaxants. CONCLUSION: Muscle relaxants are responsible for 61.6% of cases of anaphylaxis during general anesthesia. Cross-reactivity is common, as this group of drugs share a quaternary ammonium group. It is mandatory that patients be tested for both the agent responsible and cross-reactivity following an anaphylactic response. We suggest a protocol for investigation of suspected anaphylaxis.

Achilles Tendon↗
PubMed2006

Simultaneous determination of rocuronium and its eight impurities in pharmaceutical preparation using high-performance liquid chromatography with amperometric detection.

A sensitive and selective HPLC method with amperometric detection (HPLC-ED) for the determination of rocuronium bromide and its eight impurities has been developed. The analysis was performed on Hypersil 100 Silica column 5 microm (250 mm x 4.6 mm; Thermo Electron). The mobile phase consisting of 4.53 g l(-1) solution of tetramethylammonium hydroxide adjusted to pH 7.4 with 85% phosphoric acid:acetonitrile (1:9), was found the best for the separation and determination of the studied compounds. The chromatograms were recorded over 10 min using the amperometric detection at a potential +0.9 V of the glassy carbon electrode versus the reference electrode Ag/AgCl. The limit of quantitation was 45 ng ml(-1) for rocuronium and from 25 to 750 ng ml(-1) for the examined impurities. The proposed HPLC-ED method was successfully applied to the analysis of rocuronium and its impurities in Esmeron solution for injection.

Androstanols↗
PubMed2001

Quantitative determination of rocuronium in human plasma by liquid chromatography-electrospray ionization mass spectrometry.

Liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) was used for the quantification of the neuromuscular blocking agent rocuronium in human plasma. Verapamil was used as internal standard. The samples were subjected to a dichloromethane liquid-liquid extraction after ion pairing of the positively charged ammonium compound with iodide prior to LC-MS. Optimized conditions involved separation on a Symmetry Shield RP-18 column (50 x 2.1 mm, 3.5 microm) using a 15-min gradient from 10 to 90% acetonitrile in water containing 0.1% trifluoroacetic acid at 250 microl/min. Linear detector responses for standards were observed from 25 to 2,000 ng/ml. The extraction recovery averaged 59% for rocuronium and 83% for the internal standard. The limit of quantification (LOQ), using 500 microl of plasma, was 25 ng/ml. Precision ranged from 1.3 to 19% (LOQ), and accuracy was between 92 and 112%. In plasma samples, at 20 and 4 degrees C, rocuronium was stable at physiological pH for 4 h; frozen at -30 degrees C it was stable for at least 75 days. The method was found suitable for the analysis of samples collected during pharmacokinetic investigations in humans.

Androstanols↗